To enforce DAC treatment and advance in MNX1 overexpressing AML subtypes, combination therapies with other epigenetic compounds such as those that might disrupt the enhancer-promoter interaction activating MNX1 are warranted. The gene discussed is MNX1; the disease is acute myeloid leukemia.